Clinical Takeaway Randomized controlled trial evidence for cannabinoids as a primary treatment for mental health or substance use disorders remains limited and inconclusive. Current data do not firmly establish efficacy or a...
Endocannabinoid System & GLP-1 Receptors: Clinical Evidence
Clinical Takeaway GLP-1 receptor agonists, the class of medications that includes semaglutide and liraglutide, were studied using genetic methods to assess their causal effects on ten common psychiatric conditions. This Mendelian randomization...
cannabinoid clinical trials: Mental Health & Addiction Review
Clinical Takeaway Based on current randomized controlled trial evidence, cannabinoids have not been firmly established as effective or safe primary treatments for mental disorders or substance use disorders. Clinicians should interpret existing...
Adverse Childhood Experiences and Substance Use Disorders: What a Kenyan Hospital Study Shows
Adverse childhood experiences and substance use disorders are examined in this cross-sectional study of adults receiving inpatient treatment at a psychiatric referral hospital in Kenya. The paper shows that ACE exposure was extremely common and that certain childhood adversities were associated with higher odds of current tobacco, cannabis, and sedative use. Adverse childhood experiences and substance use disorders clearly belong in the same clinical conversation, but this study does not prove that childhood trauma directly caused later substance use.
`Cannabinoid Clinical Trials for Mental and Substance Disorders`
Clinical Takeaway Randomized controlled trial evidence reviewed in this meta-analysis examined cannabinoids as a primary treatment for mental health and substance use disorders, assessing both how well they work and how safe...
`Cannabinoid Clinical Trials: Mental Health & Substance Use`
Clinical Takeaway Based on randomized controlled trials, current evidence does not firmly establish cannabinoids as effective primary treatments for most mental health or substance use disorders. Adverse effects were commonly reported across...
Association of Cannabis Use Disorder Versus Other Substance Use Disorders With Psychiatric Conditions: A Propensity-Matched Retrospective Cohort Analysis.
The authors compared the risk of mental disorders between patients with cannabis use disorder (CUD) and those with other substance use disorders (SUDs). The …
Governor signs Ibogaine clinical trial bill into law – Magnolia Tribune
✦ New CED Clinical Relevance #80High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic Addiction MedicinePsychedelicsSubstance Use DisordersClinical TrialsPolicy Why This MattersIbogaine represents a potentially paradigm-shifting approach...
Genetic nurture in intergenerational transmission of substance use | Nature Communications
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic GeneticsSubstance Use DisordersFamily HistoryPreventionRisk Assessment Why This MattersThis research illuminates how parental substance use...
Cannabinoid Clinical Trials for Mental Health Disorders
Clinical Takeaway Based on randomized controlled trials, the current evidence does not firmly establish cannabinoids as effective primary treatments for mental disorders or substance use disorders. Adverse effects were consistently reported across...